Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
A phase 2 trial of Tucatinib, Eribulin and Trastuzumab in advanced solid tumours, run by Criterium, Inc., active and no longer recruiting.
Overview
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC is a phase 2 interventional study registered as NCT05458674 by Criterium, Inc., with 17 participants enrolled, started 2024-01-30 and due to reach its primary completion in 2027-06-01. Interventions recorded: Tucatinib, Eribulin and Trastuzumab.
Similar pages
not linked directly; found by shared links- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Tucatinib, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Shares Tucatinib, Trastuzumab and the tag pipeline.
- TrialBasket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Shares Tucatinib, Trastuzumab and the tag pipeline.
- TrialA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Shares Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Shares Eribulin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Eribulin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Shares Tucatinib, Trastuzumab and the tag pipeline.
- TrialSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Shares Eribulin, Metastatic cancer (cancer that has spread) and the tag pipeline.